Why the study?
Enteroviral protein 3A cysteine 38 mediates Coxsackievirus B3 protein 3A stabilization, but its role in Coxsackievirus B3 replication and virulence remained to be determined.
Does the conserved cysteine residue C38 in Coxsackievirus B3 protein 3A enhance viral replication and virulence in vitro and in vivo?
Does the conserved cysteine residue C38 in Coxsackievirus B3 protein 3A enhance viral replication and virulence in vitro and in vivo?
The highly conserved amino acid C38 in Coxsackievirus B3 protein 3A enhances viral replication and virulence, highlighting its role in viral pathogenesis.
May inform antiviral targeting of conserved 3A; leaves open relevance to enterovirus-associated cardiovascular disease.
Enteroviruses (EV) are implicated in an extensive range of clinical manifestations, such as pancreatic failure, cardiovascular disease, hepatitis, and meningoencephalitis. We recently reported on the biochemical properties of the highly conserved cysteine residue at position 38 (C38) of enteroviral protein 3A and demonstrated a C38-mediated homodimerization of the Coxsackievirus B3 protein 3A (CVB3-3A) that resulted in its profound stabilization. Here, we show that residue C38 of protein 3A supports the replication of CVB3, a clinically relevant member of the enterovirus genus. The infection of HeLa cells with protein 3A cysteine 38 to alanine mutants (C38A) attenuates virus replication, resulting in comparably lower virus particle formation. Consistently, in a mouse infection model, the enhanced virus propagation of CVB3-3A wt in comparison to the CVB3-3A[C38A] mutant was confirmed and found to promote severe liver tissue damage. In contrast, infection with the CVB3-3A[C38A] mutant mitigated hepatic tissue injury and ameliorated the signs of systemic inflammatory responses, such as hypoglycemia and hypothermia. Based on these data and our previous report on the C38-mediated stabilization of the CVB3-3A protein, we conclude that the highly conserved amino acid C38 in protein 3A enhances the virulence of CVB3.
No takes yet. Share an insight, caveat, or question.
Voß et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: